Virtu KCG Holdings LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 68.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,789 shares of the biopharmaceutical company’s stock after selling 39,974 shares during the quarter. Virtu KCG Holdings LLC’s holdings in Gilead Sciences were worth $1,330,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. BlackRock Inc. grew its stake in shares of Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Gilead Sciences by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the period. FMR LLC grew its stake in shares of Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. 76.23% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently weighed in on GILD shares. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Thursday, August 31st. Deutsche Bank reaffirmed a “buy” rating and set a $81.00 price target on shares of Gilead Sciences in a research note on Thursday, August 31st. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective on the stock in a research report on Friday, October 13th. Credit Suisse Group reiterated an “outperform” rating and issued a $85.00 price objective (up from $79.00) on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and an average price target of $85.22.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 458,486 shares of company stock worth $35,190,731. 1.30% of the stock is owned by insiders.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $75.34 on Friday. The stock has a market cap of $97,682.80, a PE ratio of 7.81, a price-to-earnings-growth ratio of -1.25 and a beta of 1.14. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.75 EPS. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.76%. Gilead Sciences’s dividend payout ratio (DPR) is 23.69%.

COPYRIGHT VIOLATION NOTICE: “Virtu KCG Holdings LLC Sells 39,974 Shares of Gilead Sciences, Inc. (GILD)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/12/02/virtu-kcg-holdings-llc-sells-39974-shares-of-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.